1. Home >
  2. M&A >
  3. Venture >
  4. United States >
  5. Minnesota >
  6. HBM Partners Invests In Cardialen

Investment Summary

HBM Partners Invests In Cardialen

On October 12, 2018, private equity firm HBM Partners invested in life science company Cardialen

Investment Highlights
  • This is HBM Partners’ 18th transaction in the Life Science sector.
  • This is HBM Partners’ 15th transaction in the United States.
  • This is HBM Partners’ 1st transaction in Minnesota.
Investment Fate
  • Cardialen was sold to a strategic buyer in 2022.

Investment Summary
Date 2018-10-12
Target Cardialen
Sector Life Science
Investor(s) HBM Partners
Deal Type Venture

Target

Cardialen

Minneapolis, Minnesota, United States
Cardialen is an early-stage medical device company dedicated to advancing implantable cardioversion and defibrillation using low energy for use as a first-line therapy to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. Cardialen was founded in 2008 and is based in Minneapolis, Minnesota.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

HBM Partners

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 2.1B USD
Size Large
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 24 of 65
Sector: Life Science M&A 18 of 56
Type: Venture M&A Deals 17 of 52
State: Minnesota M&A 1 of 1
Country: United States M&A 15 of 44
Year: 2018 M&A 6 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-08 SphingoTec

Hennigsdorf, Germany

SphingoTec develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. SphingoTec was founded in 2002 and is based in Hennigsdorf, Germany.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-08 Weisheng

Shanghai, China

Weisheng is a joint venture established to develop, manufacture and commercialize Ascendis’s endocrinology rare disease therapies in the People’s Republic of China, including Hong Kong, Macau, and Taiwan. Weisheng was founded in 2018 and is based in Shanghai, China.

Buy -
Mergr

Solution for

Product

Company

Legal